ClinicalTrials.gg
CompletedNCT02147587Updated Apr 11, 2018Results posted

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

A Phase 2 interventional study of Tofacitinib and Placebo in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 36 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-04-11.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
28th of 43
112 · median 170
Started
2014
with 2 others
Phase 2
12 of 43
2 open now
Registered
23rd of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 2, and was the 23rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have moderate to severe rheumatoid arthritis inadequately controlled by methotrexate as defined by the American College of Rheumatology (ACR) classification criteria for Rheumatoid arthritis, painful and swollen joint counts and C-reactive protein (CRP).
  • Screening CRP >3 mg/L or CDAI score > 10 at screening or at baseline before vaccination.
  • Subjects must have active disease at screening and baseline.
  • Must be at least 50 years of age or older.

Exclusion criteria

Exclusion Criteria:

  • History of receiving any varicella-zoster virus vaccine
  • Receipt of any vaccines within 6 weeks of first dose of study treatment.
  • Subjects with current infections or history of infections.
  • History of recurrent (more than one episode) of herpes zoster or disseminated (a single episode) of herpes zoster or disseminated (a single episode) of herpes simplex.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Tofacitinib 5 mg BID (oral) (70 subjects)

    Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.

    Drug: Tofacitinib

  • Placebo comparator
    Placebo tofacitinib BID (oral) (70 subjects)

    Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.

    Drug: Placebo

Interventions

  • 5 mg twice daily of tofacitinib with background methotrexate for 12 weeks

  • DrugPlacebo

    Placebo tablets twice daily with background methotrexate for 12 weeks

06

What researchers measure

Primary outcomes

  1. Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 4

    VZV-specific IgG levels as measured by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline (pre-vaccination; Day -14), Week 4 (6 weeks post-vaccination)

Secondary outcomes

  1. Fold Change From Baseline in VZV-Specific IgG Levels at Day 1 and Week 12

    Time frame: Baseline (pre-vaccination; Day -14), Day 1 (2 weeks post-vaccination), Week 12 (14 weeks post-vaccination)

  2. Absolute Values in VZV-Specific IgG Levels at Day 1, Week 4 and Week 12

    The absolute geometric mean titer (GMT) of VZV-specific IgG levels was calculated from logarithmically transformed assay values.

    Time frame: Day 1 (2 weeks post-vaccination), Week 4 (6 weeks post-vaccination), Week 12 (14 weeks post-vaccination)

  3. Percentage of Participants With >=1.5 Fold Change in VZV-Specific IgG Levels Day 1, Week 4 and Week 12

    VZV-specific IgG levels as measured by ELISA. A ratio greater than or equal to (\>=)1.5 was defined as a responder.

    Time frame: Day 1 (2 weeks post-vaccination), Week 4 (6 weeks post-vaccination), Week 12 (14 weeks post-vaccination)

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 16 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline up to Week 16

  2. Number of Participants With Zoster Vaccine-Related AEs by System Organ Class

    Zoster vaccine-related AEs included General Disorders and Administration Site Conditions (injection site erythema, pain, pruritis, rash, swelling; vaccination site erythema, pruritus, rash), Infections and Infestations (disseminated herpes zoster), and Musculoskeletal and Connective Tissue Disorders (myalgia). All zoster vaccine-related AEs were mild, except for the herpes zoster AE classified under Infections and Infestations, which was moderate in severity.

    Time frame: Baseline up to Week 16

  3. Number of Participants With Clinical Herpes Zoster Events by Severity

    Clinical herpes is manifested as mild, moderate, or severe disseminated herpes zoster.

    Time frame: Baseline up to Week 16

  4. Number of Participants With Clinically Significant Abnormal Laboratory Parameters

    Participants with the following abnormalities were discontinued from the study: 2 sequential absolute neutrophil counts (ANC) \<1000/mm\^3; 2 sequential hemoglobin values \<8.0 g/dL or decreases of \>30% from baseline value; 2 sequential absolute lymphocyte count \<500/mm\^3; 2 sequential platelet counts \<75,000/mm\^3; 2 sequential alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>=3 times the upper limit of normal (X ULN) with a total bilirubin value \>=2X ULN, elevated international normalized ratio (INR), or accompanied by signs/symptoms consistent with hepatic injury; 2 sequential ALT or AST elevations \>=5X ULN regardless of total bilirubin or accompanying symptoms; confirmed increases in serum creatinine (SCr) \>50% over the average of screening and baseline values; a confirmed positive urine pregnancy test or refusal to use appropriate contraception in a woman of childbearing potential.

    Time frame: Baseline up to Week 16

07

Results

Posted Apr 11, 2018

Participant flow

Participant flow — Overall Study
MilestonePlacebo Twice a DayTofacitinib 5 mg Twice a Day
Started5755
Completed4650
Not completed115
Withdrew: Adverse event94
Withdrew: Lack of efficacy21

Outcome measures

PrimaryFold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 4

VZV-specific IgG levels as measured by enzyme-linked immunosorbent assay (ELISA).

Time frame:
Baseline (pre-vaccination; Day -14), Week 4 (6 weeks post-vaccination)
Reported as:
Geometric mean · fold rise
Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 4
fold risePlacebo Twice a DayTofacitinib 5 mg Twice a Day
Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Immunoglobulin G (IgG) Levels at Week 41.736 (1.546 to 1.950)2.105 (1.871 to 2.369)
Statistical analysis
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · ANCOVA · Ratio of gmfr: 1.213 · 80% CI 1.033 to 1.424Ratio of GMFRs (Tofacitinib/Placebo) at Week 4
SecondaryFold Change From Baseline in VZV-Specific IgG Levels at Day 1 and Week 12
Time frame:
Baseline (pre-vaccination; Day -14), Day 1 (2 weeks post-vaccination), Week 12 (14 weeks post-vaccination)
Reported as:
Geometric mean · fold rise
Fold Change From Baseline in VZV-Specific IgG Levels at Day 1 and Week 12
fold risePlacebo Twice a DayTofacitinib 5 mg Twice a Day
Day 11.947 (1.733 to 2.186)2.005 (1.782 to 2.256)
Week 121.496 (1.323 to 1.691)1.636 (1.448 to 1.847)
Statistical analysis
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · ANCOVA · Ratio of gmfr: 1.030 · 80% CI 0.877 to 1.209Ratio of GMFRs (Tofacitinib/Placebo) at Day 1
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · ANCOVA · Ratio of gmfr: 1.093 · 80% CI 0.924 to 1.294Ratio of GMFRs (Tofacitinib/Placebo) at Week 12
SecondaryAbsolute Values in VZV-Specific IgG Levels at Day 1, Week 4 and Week 12

The absolute geometric mean titer (GMT) of VZV-specific IgG levels was calculated from logarithmically transformed assay values.

Time frame:
Day 1 (2 weeks post-vaccination), Week 4 (6 weeks post-vaccination), Week 12 (14 weeks post-vaccination)
Reported as:
Geometric mean · [gp]ELISA units/mL
Absolute Values in VZV-Specific IgG Levels at Day 1, Week 4 and Week 12
[gp]ELISA units/mLPlacebo Twice a DayTofacitinib 5 mg Twice a Day
Day 1361.603 (300.012 to 435.838)384.219 (317.477 to 464.993)
Week 4322.486 (267.557 to 388.690)403.422 (333.343 to 488.232)
Week 12278.599 (229.984 to 337.489)312.328 (257.319 to 379.096)
Statistical analysis
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · ANCOVA · Ratio of gmt: 1.063 · 80% CI 0.821 to 1.375Ratio of GMTs (Tofacitinib/Placebo) at Day 1
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · ANCOVA · Ratio of gmt: 1.251 · 80% CI 0.967 to 1.618Ratio of GMTs (Tofacitinib/Placebo) at Week 4
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · ANCOVA · Ratio of gmt: 1.121 · 80% CI 0.862 to 1.459Ratio of GMTs (Tofacitinib/Placebo) at Week 12
SecondaryPercentage of Participants With >=1.5 Fold Change in VZV-Specific IgG Levels Day 1, Week 4 and Week 12

VZV-specific IgG levels as measured by ELISA. A ratio greater than or equal to (\>=)1.5 was defined as a responder.

Time frame:
Day 1 (2 weeks post-vaccination), Week 4 (6 weeks post-vaccination), Week 12 (14 weeks post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With >=1.5 Fold Change in VZV-Specific IgG Levels Day 1, Week 4 and Week 12
percentage of participantsPlacebo Twice a DayTofacitinib 5 mg Twice a Day
Day 147.17 (37.66 to 56.85)55.56 (45.93 to 64.86)
Week 443.40 (34.06 to 53.13)57.41 (47.77 to 66.61)
Week 1243.18 (32.90 to 53.96)45.83 (35.87 to 56.07)
Statistical analysis
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · 80% CI based on Chan and Zhang method · Difference in percentages: 8.39 · 80% CI -4.05 to 20.56
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · 80% CI based on Chan and Zhang method · Difference in percentages: 14.01 · 80% CI 1.57 to 26.03
  • Placebo Twice a Day vs Tofacitinib 5 mg Twice a Day · 80% CI based on Chan and Zhang method · Difference in percentages: 2.65 · 80% CI -10.66 to 15.83
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 16 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsPlacebo Twice a DayTofacitinib 5 mg Twice a Day
AEs2116
SAEs03
Other pre-specifiedNumber of Participants With Zoster Vaccine-Related AEs by System Organ Class

Zoster vaccine-related AEs included General Disorders and Administration Site Conditions (injection site erythema, pain, pruritis, rash, swelling; vaccination site erythema, pruritus, rash), Infections and Infestations (disseminated herpes zoster), and Musculoskeletal and Connective Tissue Disorders (myalgia). All zoster vaccine-related AEs were mild, except for the herpes zoster AE classified under Infections and Infestations, which was moderate in severity.

Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Zoster Vaccine-Related AEs by System Organ Class
participantsPlacebo Twice a DayTofacitinib 5 mg Twice a Day
General and Administration Site Conditions24
Infections and Infestations01
Musculoskeletal and Connective Tissue Disorders01
Other pre-specifiedNumber of Participants With Clinical Herpes Zoster Events by Severity

Clinical herpes is manifested as mild, moderate, or severe disseminated herpes zoster.

Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Clinical Herpes Zoster Events by Severity
participantsPlacebo Twice a DayTofacitinib 5 mg Twice a Day
Mild Herpes Zoster00
Moderate Herpes Zoster01
Severe Herpes Zoster00
Other pre-specifiedNumber of Participants With Clinically Significant Abnormal Laboratory Parameters

Participants with the following abnormalities were discontinued from the study: 2 sequential absolute neutrophil counts (ANC) \<1000/mm\^3; 2 sequential hemoglobin values \<8.0 g/dL or decreases of \>30% from baseline value; 2 sequential absolute lymphocyte count \<500/mm\^3; 2 sequential platelet counts \<75,000/mm\^3; 2 sequential alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations \>=3 times the upper limit of normal (X ULN) with a total bilirubin value \>=2X ULN, elevated international normalized ratio (INR), or accompanied by signs/symptoms consistent with hepatic injury; 2 sequential ALT or AST elevations \>=5X ULN regardless of total bilirubin or accompanying symptoms; confirmed increases in serum creatinine (SCr) \>50% over the average of screening and baseline values; a confirmed positive urine pregnancy test or refusal to use appropriate contraception in a woman of childbearing potential.

Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
participantsPlacebo Twice a DayTofacitinib 5 mg Twice a Day
Number of Participants With Clinically Significant Abnormal Laboratory Parameters10

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Twice a Day—0/57 (0%)9/57 (15.8%)
Tofacitinib 5 mg Twice a Day—3/55 (5.5%)6/55 (10.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo Twice a DayTofacitinib 5 mg Twice a Day
Bile duct stoneHepatobiliary disorders0/571/55
CholangitisHepatobiliary disorders0/571/55
BronchitisInfections and infestations0/571/55
Herpes zoster disseminatedInfections and infestations0/571/55
Most frequent other events
Most frequent other events
EventPlacebo Twice a DayTofacitinib 5 mg Twice a Day
Rheumatoid arthritisMusculoskeletal and connective tissue disorders9/573/55
ArthralgiaMusculoskeletal and connective tissue disorders0/573/55

Baseline characteristics

The baseline analysis population included all randomized participants who received at least 1 dose of study drug (tofacitinib or placebo).

Age, Continuous
Age, Continuous(years)Placebo Twice a DayTofacitinib 5 mg Twice a DayTotal
Mean62.0 ± 8.761.7 ± 6.261.8 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Twice a DayTofacitinib 5 mg Twice a DayTotal
Female384280
Male191332
08

Study locations

36 sites
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Drug Shipping Address (IRB# 14-000826) Ronald Regan
    Los Angeles, California 90095, United States
  • UCLA David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • Pacific Arthritis Center Medical Group
    Santa Maria, California 93454, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Center for Arthritis and Rheumatic Diseases
    Miami, Florida 33173, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • DMI Research, Inc.
    Pinellas Park, Florida 33782, United States
  • Florida Arthritis and Osteoporosis Center
    Port Richey, Florida 34668, United States
  • Gulf Coast Medical Center
    Port Richey, Florida 34668, United States
  • Suncoast Medical Clinic
    Saint Petersburg, Florida 33705, United States
  • Sun Coast Medical Clinic
    Saint Petersburg, Florida 33710, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Health Point Medical Group, Inc.
    Tampa, Florida 33614, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Diagnostic Rheumatology And Research, PC
    Indianapolis, Indiana 46227, United States
  • Arthritis Treatment Center
    Frederick, Maryland 21702, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • The Center for Rheumatology, LLP
    Albany, New York 12206, United States
  • Buffalo Rheumatology and Medicine, PLLC
    Orchard Park, New York 14127, United States
  • Piedmont Rheumatology, P.A
    Hickory, North Carolina 28602, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • Novant Health Imaging Julian Road
    Salisbury, North Carolina 28147, United States
  • East Penn Rheumatology Associates, PC
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading LLP
    Wyomissing, Pennsylvania 19610, United States
  • Palmetto Clinical Trial Services, LLC
    Greenville, South Carolina 29601, United States
  • Arthritis Clinic
    Jackson, Tennessee 38305, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Rheumatology Consultants, PLLC
    Knoxville, Tennessee 37909-1907, United States
  • Office of John P. Lavery, MD, PA
    Allen, Texas 75013, United States
  • Baylor Research Institute Arthritis Care and Research Center
    Dallas, Texas 75231, United States
  • The Vancouver Clinic (Drug Shipment Only)
    Vancouver, Washington 98664, United States
  • The Vancouver Clinic, Inc, PS
    Vancouver, Washington 98664, United States
09

References and documents

Publications

  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. PubMed 33127856 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6. PubMed 28845577 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jun 2015, 12 months.

Results were first posted in Apr 2018, 2 years 10 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 12 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2014
First posted
May 28, 2014
StartActual
Jun 2014
Primary completionActual
Jun 2015
CompletionActual
Jul 2015
Results first posted
Apr 11, 2018
Last update
Apr 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02147587
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 28, 2014
Start date
Jun 2014
Primary completion
Jun 2015
Completion
Jul 2015
Results posted
Apr 11, 2018
Last update
Apr 11, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion